Anixa Biosciences (STU:CY71) E10: €-0.49 (As of Apr. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:CY71 Anixa Biosciences Inc STU:CY71
36 GF Score
Price €2.76
! 3 Warning Signs
View Full Analysis

What is Anixa Biosciences E10?

Anixa Biosciences STU:CY71 +3.18% 36 E10 is €-0.49 as of Apr. 2026. GuruFocus rates STU:CY71 with a GF Score™ of 36/100. The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Anixa Biosciences's adjusted earnings per share data for the three months ended in Apr. 2026 was €-0.060. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €-0.49 for the trailing ten years ended in Apr. 2026.

During the past 3 years, the average E10 Growth Rate was 6.20% per year. During the past 5 years, the average E10 Growth Rate was 4.40% per year. During the past 10 years, the average E10 Growth Rate was 7.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Anixa Biosciences was 11.70% per year. The lowest was -10.70% per year. And the median was 4.40% per year.

As of today (2026-07-15), Anixa Biosciences's current stock price is €2.76. Anixa Biosciences's E10 for the quarter that ended in Apr. 2026 was €-0.49. Anixa Biosciences's Shiller PE Ratio of today is .


Anixa Biosciences  (STU:CY71) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Anixa Biosciences E10 Related Terms


Anixa Biosciences E10 Historical Data

* Premium members only.

The historical data trend for Anixa Biosciences's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anixa Biosciences E10 Chart

Anixa Biosciences Annual Data
Trend Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23 Oct24 Oct25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.59 -0.73 -0.63 -0.52 -0.51

Anixa Biosciences Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.54 -0.53 -0.51 -0.49 -0.49

STU:CY71 vs BMEA, PMN, ATRA: E10 Comparison

For the Biotechnology subindustry, Anixa Biosciences's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anixa Biosciences Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Anixa Biosciences's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Anixa Biosciences's Shiller PE Ratio falls into.


STU:CY71
36GF Score
Anixa Biosciences Inc STU:CY71
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Anixa Biosciences E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Anixa Biosciences's adjusted earnings per share data for the three months ended in Apr. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Apr. 2026 (Change)*Current CPI (Apr. 2026)
=-0.06/333.0200*333.0200
=-0.060

Current CPI (Apr. 2026) = 333.0200.

Anixa Biosciences Quarterly Data

per share eps CPI Adj_EPS
201607 -0.118 240.628 -0.163
201610 -0.109 241.729 -0.150
201701 -0.385 242.839 -0.528
201704 0.019 244.524 0.026
201707 -0.104 244.786 -0.141
201710 -0.094 246.663 -0.127
201801 -0.090 247.867 -0.121
201804 -0.065 250.546 -0.086
201807 -0.257 252.006 -0.340
201810 -0.252 252.885 -0.332
201901 -0.219 251.712 -0.290
201904 -0.116 255.548 -0.151
201907 -0.098 256.571 -0.127
201910 -0.090 257.346 -0.116
202001 -0.117 257.971 -0.151
202004 -0.110 256.389 -0.143
202007 -0.096 259.101 -0.123
202010 -0.077 260.388 -0.098
202101 -0.074 261.582 -0.094
202104 -0.067 267.054 -0.084
202107 -0.118 273.003 -0.144
202110 -0.112 276.589 -0.135
202201 -0.115 281.148 -0.136
202204 -0.111 289.109 -0.128
202207 -0.088 296.276 -0.099
202210 -0.122 298.012 -0.136
202301 -0.074 299.170 -0.082
202304 -0.064 303.363 -0.070
202307 -0.072 305.691 -0.078
202310 -0.085 307.671 -0.092
202401 -0.092 308.417 -0.099
202404 -0.093 313.548 -0.099
202407 -0.092 314.540 -0.097
202410 -0.083 315.664 -0.088
202501 -0.097 317.671 -0.102
202504 -0.080 320.795 -0.083
202507 -0.060 323.048 -0.062
202510 -0.077 0.000
202601 -0.068 325.252 -0.070
202604 -0.060 333.020 -0.060

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of €-0.49 mean?
Anixa Biosciences (STU:CY71) has a E10 of €-0.49 as of Apr. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Anixa Biosciences and its competitors.
Is Anixa Biosciences' E10 too high?
Anixa Biosciences' current E10 is €-0.49. Overall, Anixa Biosciences has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does Anixa Biosciences' E10 compare to BMEA and PMN?
Anixa Biosciences' E10 of €-0.49 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Anixa Biosciences and its competitors. Anixa Biosciences's current E10 is €-0.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anixa Biosciences stock overvalued right now?
Anixa Biosciences (STU:CY71) has a current E10 of €-0.49. The current E10 is €-0.49. Anixa Biosciences' overall GF Score™ is 36/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Anixa Biosciences (STU:CY71), the current E10 is €-0.49 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Anixa Biosciences Business Description

Other Exchanges ANIX:USA
Address 3150 Almaden Expressway, Suite 250, San Jose, CA, USA, 95118
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.
36GF Score

Get the complete analysis for STU:CY71

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.76
Price